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Background: Superparamagnetic nanoparticles (MNPs) have been progressively explored for their potential in
biomedical applications and in particular as a contrast agent for diagnostic imaging, for magnetic drug delivery and
more recently for tissue engineering applications. Considering the importance of having safe MNPs for such
applications, and the essential role of iron in bone remodelling, this study developed and analysed novel
biocompatible and bioreabsorbable superparamagnetic nanoparticles, that avoid the use of poorly tolerated
magnetite based nanoparticles, for bone tissue engineering applications.
Results: MNPs were obtained by doping hydroxyapatite (HA) with Fe ions, by directly substituting Fe2+ and Fe3+
into the HA structure yielding superparamagnetic bioactive phase. In the current study, we have investigated the
effects of increasing concentrations (2000 μg/ml; 1000 μg/ml; 500 μg/ml; 200 μg/ml) of FeHA MNPs in vitro using
Saos-2 human osteoblast-like cells cultured for 1, 3 and 7 days with and without the exposure to a static magnetic
field of 320 mT. Results demonstrated not only a comparable osteoblast viability and morphology, but increased in
cell proliferation, when compared to a commercially available Ha nanoparticles, even with the highest dose used.
Furthermore, FeHA MNPs exposure to the static magnetic field resulted in a significant increase in cell proliferation
throughout the experimental period, and higher osteoblast activity.
In vivo preliminary results demonstrated good biocompatibility of FeHA superparamagnetic material four weeks
after implantation into a critical size lesion of the rabbit condyle.
Conclusions: The results of the current study suggest that these novel FeHA MNPs may be particularly relevant for
strategies of bone tissue regeneration and open new perspectives for the application of a static magnetic field in a
clinical setting of bone replacement, either for diagnostic imaging or magnetic drug delivery.
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reproduction in any medium, provided the orTo regenerate bone tissue, the body relies on materials
that it uses like a template to regenerate tissue [1]. The
body is very capable of healing and regenerating itself
when the defects are small. However, larger defects can-
not be healed without making use of an aid, such as the
employment of biomaterials. There are multiple criteria
to design materials for bone regeneration, which include:
osteoinductivity (capable of promoting the differenti-
ation of progenitor cells down an osteoblastic lineage),
osteoconductivity (support bone growth and encourage
the ingrowth of surrounding bone), and osteointegration
(integrative to the surrounding bone), biocompatibilityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fective resorbability, similar mechanical properties to
bone (so as to perform its load-bearing function), ability
to shape to a wide range of defect geometries, and finally
must meet all regulatory requirements for clinical use
[1,2].
In the last decades, nanotechnology has been progres-
sively used to enhance the above-mentioned bone tissue
engineering strategies [3]. In particular, nanotechnology
has been employed to overcome some of the current
limitations associated with bone regeneration methods,
including insufficient mechanical strength of scaffold
materials, ineffective cell growth and osteogenic differ-
entiation at the defect site [4]. In fact, decreasing the
material size into the nanoscale, the surface area, the
surface roughness and the surface area to volume ratios
are dramatically increased leading to superior materials
physiochemical properties and mimicking the hierarch-
ical nanostructure of native tissue [5,6].
Moreover, recently, the usage of superparamagnetic
nanoparticles (MNPs) for biological and medical pur-
poses has been increasing [7-9]. MNPs contain a mag-
netic core (usually composed of magnetite Fe3O4 or
maghemite γ-Fe2O3) that confers the unique feature of
reacting to magnetic forces. This core is usually coated
with an inert layer that minimises hydrophobic interac-
tions, enhancing colloid dispersion and biocompatibility.
MNPs have been used in the last decade for in vitro and
in vivo applications, as hyperthermia [10], contrast agent
for diagnostic imaging [11,12], magnetic drug delivery
[13], and cell mechanosensitive receptor manipulation to
induce cell differentiation [14]. Whereas only few
authors proposed approaches for tissue engineering and
in particular its use in orthopaedic applications remains
largely uninvestigated to date [10,15,16]. This is despite
the promise of iron to increase bone health. In fact the
beneficial link between iron and bone density has been
demonstrated in clinic by the association of dietary iron
and a healthy bone mineral density [17,18].
Although the role of iron in bone accrual has received
little attention, a few studies have previously shown that
iron restriction can have an inhibitory effect on the
mineralization of osteoblasts in vitro and experimental
evidence also suggests that there may be some positive
association between iron metabolism and the in vitro
proliferation of bone or non-bone cell lines [19-21].
Considering the importance of having non-toxic
MNPs for the above-mentioned applications, and the
important role of iron in bone regeneration and remod-
elling, this study aimed to analyse for the first time novel
superparamagnetic bioactive and bioresorbable nanopar-
ticles obtained by doping hydroxyapatite (HA) with Fe
ions in ideal condition aimed at limiting the formation of
poorly tolerated magnetic secondary phase (i.e. Fe3O4)and able to be manipulated in situ by magnetic forces
[22]. In fact, the use of magnetic stimulation in the field of
regenerative medicine is emerging as one of the most at-
tractive concepts [23-25].
In this context, the present study investigated the
in vitro biocompatibility and bioactivity of FeHA nano-
particles in cultures of osteoblast-like cells in the ab-
sence and presence of an externally applied static
magnetic field. These studies were followed subsequently
by a pilot study to verify in vivo biocompatiability of
these innovative FeHA materials.
Results and discussions
Superparamagnetic FeHA nanoparticles have been
synthesized following a neutralization method in which
both Fe species are simultaneously introduced under
controlled synthesis conditions. Following this synthesis
method, during the stage of HA formation, the crystallo-
graphic position Ca(1) and Ca(2) of the apatite lattice
are selectively substituted by iron species, Fe3+ and Fe2+
respectively [26] generating two distinct interacting
structural domains whose interaction provide an intrin-
sic superparamagnetism [22]. The in vitro study was per-
formed using human osteoblast-like cells firstly to
evaluate any effect of novel FeHA nanoparticles on cell
culture compared to HA nanoparticles already commer-
cialized and used in the clinic as bone filler or as the
primary component of several bone substitutes. Subse-
quently our attention was focused on the effect of static
magnetic field on FeHA MNPs in cell culture. After
obtaining positive and encouraging in vitro results, this
magnetic biomaterial was tested for the first time in vivo
in a pilot experiment in a rabbit condyle critical bone
defect.
Superparamagnetic FeHA nanoparticles characterization
Inductively coupled plasma (ICP) analysis evaluating the
Fe, Ca and PO4 ions concentration, showed evidences of
the replacement of Ca with Fe. In fact (Fe +Ca)/P molar
ratio was very close to the theoretical one (Ca/P = 1.67)
while the Ca/P = 1.41 molar ratio was lower than the
theoretical one confirming the replacement of Ca with
Fe ions [22].
As detected by X-ray powder diffraction (XRD) analysis
(Figure 1), the synthesis method employed leads to a low
crystalline apatite with a crystallinity extent much lower
than the non-substituted HA prepared at the same
temperature with very low content of magnetite (<2 vol.%)
as secondary phase. Moreover, XRD structural analysis also
gave the evidence of the substitution of Fe ions into the
HA lattice (Figure 1A): computer simulations clearly indi-
cate that the Fe2+ and Fe3+ both occupy different Ca2+
positions in the HA lattice so that Fe ions are not situated
in cell interstitial position but in Ca-substituting position.
Figure 1 FeHA nanoparticles characterization. A) XRD analyses profiles obtained from FeHA and HA nanopowders synthesized at the same
temperature and conditions. FeHA spectra underline a lower crystallinity and a little amount of magnetite (*) (~ 2 vol.%) as secondary phase. B,C)
TEM micrographs showing FeHA MNPs with needle-like morphology and the absence of Fe agglomerates inside the particles. D) Magnetization
curve obtained from the analysis of FeHA MNPs, which displays a typical superparamagnetic behaviour.
Panseri et al. Journal of Nanobiotechnology 2012, 10:32 Page 3 of 10
http://www.jnanobiotechnology.com/content/10/1/32Moreover, by Rietveld analysis an increase of the a axis
from 9.4218(5) to 9.4557(1) and a decrease of c axis
from 6.8813(3) to 6.8785(1) was detected as expected in
the case of Ca substitution with ion species having a
lower radius.
FeHA nanopowder morphology was investigated using
TEM analysis that showed a very low concentration of
dark spots (5-10 nm in size) corresponding to inclusions
of iron rich phases (Figure 1B, C). In addition TEM in-
vestigation confirmed that the quasi-amorphous calcium
phosphate matrix contains iron uniformly distributed
and showed calcium phosphate particles with needle-like
morphology, rather heterogeneous in size, 5-20 nm in
width and up to 50-80 nm in length (Figure 1B, C).
For FeHA nanopowders the magnetization curve as
function of the applied magnetic field showed the typ-
ical superparamagnetic behaviour of single-domain
magnetic nanoparticles (Figure 1D). Contrary to what
would be expected on the basis of the amount and ag-
gregate size of magnetite present in the powder as sec-
ondary phase and detected by XRD, the saturation
magnetization value of the FeHA nanopowder was
higher (4.0 - 4.2 emu/g) confirming the intrinsic mag-
netic property of the powder due to the substitution
of iron ions in the HA lattice [22].In vitro evaluation of biocompatibility and cell
morphology
In vitro evaluation of the effects of the novel FeHA MNPs
on osteoblast-like cell culture was conducted. In detail,
24 hours after Saos-2 cells were plated, 4 different concen-
trations of FeHA and HA nanoparticles, in a range from
200 μg/ml up to 2000 μg/ml, were added to the culture
medium. It should be noted that the concentrations used
in this study were significantly higher than the normal
concentration used in several nanoparticles studies, in fact
even the lowest concentration (200 μg/ml) is in many
cases nearly the highest concentration adopted by several
groups [21,27,28]. In this regard, the aim of this study was
to verify any toxic effects induced by the FeHA MNPs
compared to the HA nanoparticles, keeping in mind fu-
ture in vivo applications, where high nanoparticle accu-
mulation in the cells could influence cell behaviour.
The cell culture was analysed for 7 days for cell viability,
with the Live/Dead assay showing for both FeHA and HA
groups a very high ratio of viable cells at each experimen-
tal time point with no significant differences among the
two groups, with a range respectively between 98.0±0.5%
and 100% at day 1, 96.7±0.4% and 99.1±0.5% at day 3,
97.3±0.5% and 99.7±0.2% at day 7 (Figure 2). Furthermore,
the presence of FeHA MNPs in the cell culture media
Figure 2 Analysis of cell viability. Cell viability was analysed by the Live/Dead assay (n = 2). Calcein AM stains for live cells in green, EthD-1
stains for dead cells in red. A) HA 1000 μg/ml at day 3. B) FeHA 1000 μg/ml at day 3. C) HA 200 μg/ml at day 7. D) FeHA 200 μg/ml at day 7.
Scale bars: A,B) 200 μm. C,D) 100 μm.
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nanoparticles. In fact, analysing the DNA content, signifi-
cant differences were seen at day 3 and day 7 FeHA MNPs
group and HA group (Figure 3). While at day 1 there was
no statistic significant difference among the superparamag-
netic and the control nanoparticles, there was a trend
showing a higher number of cells in FeHA groups com-
pared to the HA groups. These data are in agreement with
several studies where different types of magnetic particles
were used and they influence cell proliferation [21,28,29].
The obtained results demonstrate the good biocom-
patibility of the FeHA MNPs. In fact not only did they
not reduce the cell viability (at even with the highest
FeHA MNPs concentration), they also enhanced cell
proliferation compared to respective HA groups. Look-
ing in detail at the cell morphology, nanoparticles were
seen accumulated in the cytoplasm (Figure 4A,B) and
even when the cells showed high MNP accumulation
they remained firmly attached to the well surface. This
fact suggests that the novel intrinsically magnetic FeHA
MNPs were well tolerated by the cells in a similar way
as the HA groups, where HA serves as the maincomponent of several bone substitutes already used in
clinical applications, and have also been shown to induce
cell proliferation.
As previously stated, we envisage a prominent role of
FeHA MNPs will be in biomedical applications, particu-
larly in conjunction with an applied magnetic field. Due
to their superparamagnetic properties, the FeHA MNPs
become magnetized upon exposure to a magnetic field
without showing permanent magnetization (remanence)
once the field is turned off.Effect of the in vitro application of a static magnetic field
As we have demonstrated similar biocompatibility of
FeHA MNPs to HA particles, we focused our attention
on studies designed to study how the presence of an ex-
ternally applied static magnetic field (SMF) could modu-
late the cell proliferative effects and bone regenerative
capacity induced by these MNPs. All the experiments
were conducted with or without applying a 320 mT
SMF on cells seeded with the 4 different concentrations
of FeHA MNPs.
Figure 3 Cell proliferation assay. The Picogreen DNA content assay was performed on cultures of osteoblast-like cells seeded with 4 different
concentrations of HA and FeHA nanoparticles at 1, 3 and 7 days of culture (n = 5). n.s. = not significant; *** p≤0.001.
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the cellular effects of static magnetic field at the cellular
level, compared to those of extremely low frequency
electromagnetic fields. While several studies showed that
exposure to static magnetic fields alone has no or ex-
tremely small effects on cell growth and genetic toxicity
regardless of the magnetic density, in combination with
other external factors such as ionizing radiation and
some chemicals, there is evidence to strongly suggest
that a SMF modifies their effects [30]. Our findings are
strongly in agreement with these data. In fact, after con-
firming that SMF on cells in culture by itself did not
affect cell behaviour (data not shown), our study with
FeHA MNPs have confirmed a statistically significant in-
crease in cell proliferation from day 1 to day 7 between
FeHA groups with SMF application compared to groups
without magnetic field application (Figure 5). In detail,
the 200 μg/ml FeHA MNPs concentration induce a
higher cell proliferation compared to the 2000 μg/ml
FeHA MNPs only with exposure to the SMF, suggesting
that the lowest concentration of nanoparticles actsFigure 4 Analysis of cell morphology. Cells were spread with good mor
that have been internalized by cells. A) FeHA 500 μg/ml at day 3, cells stain
day 7, bright field image. Scale bars: 50 μm.synergy with the magnetic field to stimulate cell prolif-
eration (Figure 5).
Furthermore, with respect to osteoblast activity on
each condition, AP activity seemed to be influenced by
the synergic effect of FeHA MNPs and SMF, with a sig-
nificant effect at day 3, indicating that there might be
also a positive effect on osteoblast activity given by the
presence of SMF (Figure 6).In vivo pilot experiment
In order to assess how well our in vitro observations
translate in vivo, we tested the biocompatibility of FeHA
materials in a pilot animal study of bone repair (a rabbit
critical bone defect model). For this purpose FeHA
nanopowder was processed in order to obtain a granu-
late (400-600 μm) more easily handled and similar to
bone fillers already used in clinical applications. The
FeHA granules were not stabilized with the same ther-
mal treatment applied to the reference material to avoid
chemical-physical modification of the nanostructure andphology and firmly attached to the surface. Black spots are the MNPs
ed with Calcein AM in green and EthD-1 in red. B) FeHA 200 μg/ml at
Figure 5 Cell proliferation assay in the presence of a static magnetic field. The Picogreen DNA content assay was performed on cultures of
osteoblast-like cells seeded with 4 different concentrations of FeHA MNPs at 1, 3 and 7 days of culture, either in the presence or absence of a
static magnetic field (SMF) (n = 5). ** p≤0.01; *** p≤0.001.
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section).
At 4 weeks post-implantation, macroscopic evaluation
showed the HA and FeHA biomaterials to be in the
proper position and there was no evidence of haematoma,
edema, infection or tissue necrosis in either bone and
peri-implant soft tissue associated with control or mag-
netic implants. Bone tissue was well visible around the
biomaterials in both groups demonstrating a good bone
integration of FeHA granules (Figure 7). In detail, between
the granules, the magnetic FeHA group showed more im-
mature bone not yet completely mineralized stained with
Toluidine Blue respect to HA granulate control group
(Figure 7). We speculate that this is probably due to the
lower physical stability of the FeHA granules in compari-
son with the reference material, which has been subjected
to the thermal treatment. This would result in a less com-
pact material with a higher specific surface available for
bone integration, possibly making FeHA more bioactive
than control. In the long term these characteristics might
positively influence tissue regeneration and stability and
reduce biomaterial resorbability.Figure 6 Alkaline phosphatase activity assay in the presence of a stat
concentrations of FeHA MNPs seeded with human osteoblast-like cells at 1
field (SMF) (n = 5). * p≤0.05.In any case, the aim of this in vivo study was merely to
verify the histocompatibility of these new magnetic
FeHA particles that for the first time were implanted
in vivo. These preliminary but encouraging results indi-
cate this material might be suitable for the development
of a more complete in vivo study including the applica-
tion in situ of a static magnetic field.Conclusions
Overall, the in vitro results showed that the novel super-
paramagnetic FeHA MNPs not only did not reduce cell
viability, but they enhance cell proliferation compared to
HA particles controls already used in clinical application.
Moreover, the positive effect of these nanoparticles was
significantly increased when a SMF was applied.
In conclusion, the magnetic properties of the new
FeHA phase open the door of regenerative medicine to a
conceptually new family of biomimetic materials able to
be biologically manipulated or “activated” in situ by
means of an external magnetic field. Additionally, the
wider field of theranostics may benefit of solutionsic magnetic field. AP activity was measured with different
, 3 and 7 days, either in the presence or absence of a static magnetic
Figure 7 Histological evaluation of the in vivo implanted HA and FeHA granules. Toluidine Blue, Acid Fucsin and Fast Green staining shows
similar histocompatibility for both biomaterials 4 weeks after implantation (n = 6). A) HA control group, B) FeHA group. Scale bars: 1 mm.
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Methods
Synthesis of FeHA nanoparticles
FeHA nanoparticles were prepared according to the
method described in our previous study [22]. Briefly, a
basic suspension of calcium hydroxide Ca(OH)2
(Aldrich, 95 wt% pure, 50 g in 400 ml of H2O) was
stirred and heated up to 40°C. FeCl24H2O (Aldrich, ≥
99 wt% pure, 12.74 g in 75 ml of H2O) and FeCl36H2O
(Aldrich, 97 wt% pure, 17.86 g in 75 ml of H2O) solu-
tions were contemporarily added to the basic suspension
as sources of Fe2+ and Fe3+ ions. The total amounts of
iron ions with respect to calcium ions were adjusted so
as to obtain: Fe/Ca = 20 mol%.
Soon after a phosphoric acid (Aldrich, 85 wt% pure,
44.40 g in 300 ml of H2O) solution was drop-wise added
into a basic suspension of calcium hydroxide containing
iron ions, over a period of 2 h, under constant heating
and stirring.
The reaction products were kept in suspension by con-
stant stirring and heating for 1 h and then left ageing for
24 h at room temperature without further stirring. The
precipitate was separated from mother liquor by centri-
fugation, then washed with distilled water and centri-
fuged three times; finally it was freeze-dried and sieved
at 150 μm.
For the in vivo test, FeHA nanopowder was processed
in order to obtain a more stable granulate (400-600 μm).
In detail, the powder was hydrated with distilled water
and agglomerated. Agglomerates were dried at 40°C for
48 h and sieved in the range 400-600 μm. Glass vials
containing 0.5 g of granulates were prepared and steri-
lized with 25 γ-ray. The control group consisted of a
bone filler made of HA granulate of identical size (400-
600 μm), already commercially available, and stabilized
for one hour at 300°C (FinGranule, Finceramica Faenza
Spa, Italy).FeHA nanoparticles characterization
FeHA phase composition was determined by X-ray pow-
der diffraction (XRD), performed by a D8 Advance Dif-
fractometer (Bruker, Karlsruhe, Germany) using CuKa
radiation at 40 kV and 40 mA. XRD spectra were
recorded in the 2 h range 10–60° or 15–120°, with a step
size of 0.02 and a counting time of 1 s (corresponding to
185 s using a conventional detector). Quantitative evalu-
ation of phase compositions and cell parameters was
performed by full-profile Rietveld analysis of the
XRD spectrum (TOPAS v4.2, Bruker AXS, Karlsruhe,
Germany). Computer simulation of XRD patterns of
FeHA powders based on structural models was car-
ried out by the aid of the software Powder cell 2.4
(W. Krause & G. Nolze, 2000).
ICP-OES quantitative analysis made use of inductively
coupled plasma – atomic emission spectrometry (ICP-
AES: Liberty 200, Varian, Clayton South, Australia) to
determine the overall content of Ca, P and Fe. Samples
were previously prepared as follows: 20 mg of powder
were dissolved in 2 ml of HNO3 (Aldrich, 65 wt%
pure) and the solution volume was increased up to
100 ml with deionised water. The obtained values were
expressed in terms of (Fe + Ca)/P mol, Ca/P mol and
Fe/Ca molar %.
The analysis of powder morphology was carried out by
high-resolution transmission electron microscopy
(HRTEM) analyses, performed by a JEOL JEM 3010-
UHR, operating at 300 kV.
Magnetic measurements were performed at higher
field in a superconducting quantum interference device
(SQUID) magnetometer from Quantum Design (San
Diego, CA, USA), capable of operating from 1.8 to
350 K under a maximum applied magnetic field of
H= 5 N A-1 m-1.
Cell culture
Saos-2 Human Osteoblast-like cells purchased from
Lonza (Italy) were cultured in Dulbecco Modified Eagle’s
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streptomycin (100 U/ml-100 μg/ml) supplemented with
10% fetal bovine serum and kept at 37°C in an atmos-
phere of 5% CO2. Cells were detached from culture
flasks by trypsinization and centrifuged; cell number and
viability were assessed with the trypan-blue dye exclu-
sion test.
Saos-2 were plated at a density of 2.5 × 104 cells/well
in 24-well plates. 24 h after seeding, different concentra-
tions of nanoparticles were added to the cell culture
(2000 μg/ml; 1000 μg/ml; 500 μg/ml; 200 μg/ml). Nano-
particles were sonicated and vortexed before being
added to the cells. Cells were incubated under standard
conditions (37 °C, 5% CO2) with cell culture medium
supplemented with 10 μg/ml ascorbic acid (Sigma) and
5 mM β-glycerophosphate (Sigma) for osteoblast activa-
tion, for 1, 3 and 7 days. Culture media was changed
every other day. The experiments were conducted either
with or without applying a static magnetic field (SMF) of
320 mT (MagnetoFACTOR-24, Chemicell, Germany)
under the plates. All cell handling procedures were per-
formed in a sterile laminar flow hood.
Live/dead assay
Live/Dead Viability/Cytotoxicity assay kit for mamma-
lian cells (Invitrogen) was performed according to man-
ufacturer's instructions. Briefly, cells were washed with
1x PBS for 5 min and incubated with Calcein acetoxy-
methyl (Calcein AM) 2 μM plus Ethidium homodimer-1
(EthD-1) 4 μM for 15 min at 37°C in the dark. Cells
were washed with 1x PBS for 5 min and images acquired
by a confocal microscope Fluoview FV1000 (Olympus).
The live and dead cells ratio was determined by quanti-
fying the number of cells in 3 fields at the same
magnification for each HA and FeHA nanoparticles
concentration at each time point without magnetic field
application. Two samples per time point were analysed for
each group.
Cell proliferation assay
Total DNA content was quantified using the Quanti-iTTM
PicoGreen dsDNA Assay Kit (Invitrogen) assay following
the manufacturer’s suggested protocol. Seeded wells were
washed with 1x PBS and then incubated with 1 ml 1x PBS
with 0.1% (v/v) Triton-X for cell lysis. Collected cells were
centrifuged at 11000 rpm for 1 min. 25 μL of supernatant
was added to 175μL of PicoGreenW reagent working solu-
tion in a 96-well plate. Fluorescence of the samples was
measured with a microplate reader (Tecan, Research Tri-
angle Park, NC) with excitation and emission wavelengths
of 485 and 535 nm, respectively. A standard curve of
fluorescence versus DNA concentration was created, from
which the DNA concentration values for each sample
were determined. The total number of cells in the samplewas determined by converting the total DNA concentra-
tion to cell number using the conversion factor of 7.7 pg
DNA/cell [31]. Five samples per condition per time point
were analysed.
Alkaline phosphatase assay
Cell Alkaline Phosphatase (AP) activity was quantified
using an enzymatic assay based on the hydrolysis of p-
nitrophenyl phosphate (pNP-PO4) to p-nitrophenol
(pNP) [32]. Briefly, 25 μl of cell lysate, obtained as previ-
ously described (see the “cell proliferation assay” para-
graph), was added to pNP-PO4 solution (Sigma-Aldrich)
and allowed to react at 37°C. Absorbance was read at 0,
1, 2 and 3 min at λmax of 405 nm, using a microplate
reader (Tecan, Research Triangle Park, NC) and AP ac-
tivity calculated by cross-reference to a standard curve
of nanomoles of p-nitrophenol liberated per cell. AP activ-
ity was normalized to total cellular content, as measured
by the Picogreen assay. Five samples were analysed per
condition per each time point.
In vivo pilot experiment and histological analysis
The study was performed in accordance with EC guide-
lines (EC Council Directive 86/609, 1986) and the Italian
legislation on animal experimentation (Decreto L. vo
116/92). The research protocol on animals has been
approved by the Ethical Committee of Rizzoli Ortho-
paedic Institute and by the responsible public author-
ities. Six male rabbits (Oryctolagus cuniculus, Charles
River, Lecco, Italy), 2.4 ± 0.2 kg body weight, were
housed at a controlled temperature of 22 ± 1°C and rela-
tive humidity of 55 ± 5% in single boxes and fed a stand-
ard diet (Mucedola, Milano, Italy) with filtered tap water
ad libitum. After quarantine of at least 10 days, the ani-
mals were fasted for 24 hours before surgery. The ani-
mals were subjected to surgery to implant the tested
biomaterials at the distal femoral epiphysis under gen-
eral anaesthesia and in aseptic conditions. After having
shaved and disinfected the posterior legs, the animals
underwent a lateral longitudinal incision of lateral fem-
oral condyle. Femoral lateral condyle trabecular bone
was cross-sectionally drilled at low speed and a profuse
irrigation with cold sterile 0.9% NaCl solution was main-
tained throughout the process to prevent the risk of
bone necrosis. A critical bone defect of 6.00 mm in
diameter and 8.00 mm in depth was made in each lateral
femoral condyle. Defects were filled with FeHA granules
and with the HA granules in the contralateral condyle as
a control group. For each defect, approximately 0.5 g
granules, sterilized by 25 kGy γ-ray radiation, were used.
Finally, the skin was sutured. General anaesthesia was
induced by an intramuscular injection of 44 mg/kg keta-
mine (Imalgene 1000, Merial Italia S.p.A, Milan, Italy)
and 3 mg/kg xylazine (Rompun, Bayer SpA, Milano,
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min) mixture and 2.5% isofluorane (Forane, Abbot SpA,
Latina, Italy).
Post-operatively, antibiotics and analgesics were admi-
nistered: 0.6 ml/kg flumequil (Flumexil, (FATRO SpA,
Bologna, Italy) and 0.1 ml/kg/day metamizole sodium
(Farmolisina, Ceva Vetem SpA, Monza-Brianza, Italy).
At 4 weeks after surgery, the animals were pharmaco-
logically euthanized with intravenous administration of
Tanax (Hoechst, Frankfurt am Main, Germany), under
general anaesthesia. The operated bone segments were
excised and stripped of soft tissue and the presence of
haematomas, edema and inflammatory tissue reactions
were macroscopically evaluated. The bone segments
were fixed in 4% buffered paraformaldehyde for 24 hours,
dehydrated in a graded series of alcohol and finally em-
bedded in a methyl methacrylate resin (Merck Schu-
chardt OHG, Hohenbrunn, Germany). Using a saw
microtome (Leica SP1600, Leica Microsystems Srl, Italy),
three consecutive central sections to the major axis of
the implant for each bone segment were cut
(60 ± 20 μm) and polished (Struers Dap-7, Struers Tech
A/S, Rodovre/Copenaghen, Denmark). Then, thinned
sections (30 ± 10 μm) were stained with Toluidine Blue,
Acid Fucsin and Fast Green.
Statistical analysis
Results were expressed as MEAN±SEM plotted on graph
(n = 5). Statistical analysis was performed using two-way
ANOVA, followed by Bonferroni’s post-hoc test, for the
analysis of magnetic field effect, time effect and mag-
netic field versus time effect. Analysis of differences be-
tween groups, for each time point, was performed by
one-way ANOVA, followed by Tukey’s post-hoc test. All
statistical analyses made were performed using Graph-
Pad Prism software (version 5.0), with α=0.05.
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